Enliven TherapeuticsELVN
ELVN
About: Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
Employees: 57
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
67% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 24
14% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 8 (+1) [Q3]
10% more funds holding
Funds holding: 93 [Q2] → 102 (+9) [Q3]
6% more capital invested
Capital invested by funds: $1.14B [Q2] → $1.22B (+$73.3M) [Q3]
3.18% less ownership
Funds ownership: 104.13% [Q2] → 100.95% (-3.18%) [Q3]
77% less call options, than puts
Call options by funds: $3K | Put options by funds: $13K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
56%
upside
Avg. target
$39
67%
upside
High target
$42
81%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
BTIG Justin Zelin 0% 1-year accuracy 0 / 8 met price target | 81%upside $42 | Buy Initiated | 13 Dec 2024 |
Baird Colleen Kusy 33% 1-year accuracy 7 / 21 met price target | 73%upside $40 | Outperform Maintained | 15 Nov 2024 |
Jones Trading Soumit Roy 27% 1-year accuracy 3 / 11 met price target | 56%upside $36 | Buy Initiated | 31 Oct 2024 |
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 37 / 155 met price target | 60%upside $37 | Buy Reiterated | 1 Oct 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo. , Nov. 13, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2024, and provided a business update, including highlights of pipeline progress.
Neutral
PRNewsWire
1 month ago
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
BOULDER, Colo. , Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m.
Positive
Yahoo Finance
2 months ago
Why Enliven is this analyst's top biotech stock pick
Salim Syed, Mizuho Americas managing director and senior analyst, joins the latest edition of Good Buy or Goodbye to discuss his top and bottom picks in the pharmaceutical industry. Syed points to Enliven Therapeutics (ELVN) as his top pick, believing that its drugs in development are promising.
Positive
Zacks Investment Research
2 months ago
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why
Enliven Therapeutics, Inc. (ELVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Neutral
GlobeNewsWire
2 months ago
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (NCT05304377) at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference.
Positive
Zacks Investment Research
2 months ago
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
Enliven Therapeutics, Inc. (ELVN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
GlobeNewsWire
3 months ago
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic.
Positive
Zacks Investment Research
3 months ago
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 58.8% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
4 months ago
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet
The consensus price target hints at a 43% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
6 months ago
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:
Charts implemented using Lightweight Charts™